ADVERTISEMENT
Bevacizumab-awwb Safe, Effective Among Patients With Metastatic Colorectal Cancer
Bevacizumab-awwb was the first biosimilar to bevacizumab approved by the US Food and Drug Administration; however, real-world data on effectiveness and safety remain limited and may help address barriers to utilization. A study from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting offered new, real-world data to the literature.
Ran Jin, MD, PhD, Amgen Inc, Thousand Oaks, CA, and colleagues identified 129 patients aged ≥18 years who had a confirmed diagnosis of metastatic colorectal cancer (mCRC) (initial presentation on or after 1 January 2018) and initiated bevacizumab-awwb between 19 July 2019 and 30 April 2020. A retrospective medical chart review was conducted to evaluate patient clinical characteristics and outcome data. The current analysis focused on the subset of patients who initiated first-line (1L) bevacizumab-awwb containing therapy (with no prior use of RP) to evaluate incidence of events of interest (EOIs) and overall survival (OS) probability using Kaplan-Meier analysis. Patients were followed from the initiation of 1L therapy until death, end of record, or end of study period (June 2021), whichever occurred first.
The majority of patients (78.3%) were treated at clinical oncology practices in a community setting (median age: 60.5 years, 53.5% male). 34.9% of patients had non-metastatic disease (stage of I/II/III) at the initial diagnosis and 38.8% had undergone surgical resection. Median duration of available follow-up data was 10.7 months (range: 0.69-22.4). During the study period, 100 out of 129 patients had disease progression, of which 46 died. The Kaplan-Meier analysis showed that 12-month OS probability was 71.4% (95% CI: 61.0%-79.5%). During treatment with bevacizumab-awwb, 20 EOIs were reported in 18 patients (14.0%). Distribution of events and their management are presented in the Table. None of these EOIs resulted in death.
“Biosimilar bevacizumab-awwb appeared to be well tolerated, with observed EOIs being manageable, and 12-month OS probability of > 70% for treating patients with mCRC in the real-world setting,” wrote Dr Jin and colleagues.
Jin R, et al. Real-world outcomes among patients with metastatic colorectal cancer treated first line with bevacizumab-awwb. Abstract presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago, IL, and virtual. Abstract e15581.
